Time interval between neoadjuvant radio-chemotherapy and surgery in rectal cancer: is the long interval correct for all patients?


Journal

Minerva surgery
ISSN: 2724-5438
Titre abrégé: Minerva Surg
Pays: Italy
ID NLM: 101777295

Informations de publication

Date de publication:
Jun 2022
Historique:
pubmed: 29 5 2021
medline: 27 5 2022
entrez: 28 5 2021
Statut: ppublish

Résumé

Optimal time between neoadjuvant radio-chemotherapy period and surgery remains controversial in patients with rectal cancer: an increasing number of studies show results in favor of a long interval. We conducted a retrospective analysis of the cases of low-middle rectal adenocarcinoma undergoing neoadjuvant RT-CT and surgery: the primary endpoint was the complete pathological response rate and the secondary endpoint the rate of complications. We analyzed cases from 1/01/2003 to 31/12/2018 divided in two periods: from 2003 to 2010 (23 pts) and from 2011 to 2018 (23 pts). The two periods were characterized by two different surgical teams which use different time intervals (≤ vs. >8 weeks). The pCR rate is 21.7% in both groups; as regards the complications, the difference between the two groups is in grade IIIb: 8.7% in the first group and 17.4% in the second group (P=0.66). Although our study is based on a small number of patients, it shows the same rate of pCR with respect to two different time intervals; this suggests the need for studies based on the division of patients into subgroups and the evaluation of different time intervals in order to reach the best oncological outcomes.

Sections du résumé

BACKGROUND BACKGROUND
Optimal time between neoadjuvant radio-chemotherapy period and surgery remains controversial in patients with rectal cancer: an increasing number of studies show results in favor of a long interval.
METHODS METHODS
We conducted a retrospective analysis of the cases of low-middle rectal adenocarcinoma undergoing neoadjuvant RT-CT and surgery: the primary endpoint was the complete pathological response rate and the secondary endpoint the rate of complications. We analyzed cases from 1/01/2003 to 31/12/2018 divided in two periods: from 2003 to 2010 (23 pts) and from 2011 to 2018 (23 pts). The two periods were characterized by two different surgical teams which use different time intervals (≤ vs. >8 weeks).
RESULTS RESULTS
The pCR rate is 21.7% in both groups; as regards the complications, the difference between the two groups is in grade IIIb: 8.7% in the first group and 17.4% in the second group (P=0.66).
CONCLUSIONS CONCLUSIONS
Although our study is based on a small number of patients, it shows the same rate of pCR with respect to two different time intervals; this suggests the need for studies based on the division of patients into subgroups and the evaluation of different time intervals in order to reach the best oncological outcomes.

Identifiants

pubmed: 34047530
pii: S2724-5691.21.08770-0
doi: 10.23736/S2724-5691.21.08770-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

245-251

Auteurs

Antonio Costanzo (A)

Unit of Surgical Oncology, ASST Bergamo Ovest, Treviglio, Bergamo, Italy.

Antonio Ghidini (A)

Medical Oncology, Casa di Cura Igea, Milan, Italy - antonioghidini@hotmail.com.

Fausto Petrelli (F)

Unit of Oncology, Department of Medical Sciences, ASST Bergamo Ovest, Treviglio, Bergamo, Italy.

Luca Turati (L)

Unit of Surgical Oncology, ASST Bergamo Ovest, Treviglio, Bergamo, Italy.

Valentina Rampulla (V)

Unit of Surgical Oncology, ASST Bergamo Ovest, Treviglio, Bergamo, Italy.

Antonio Varricchio (A)

Unit of Surgical Oncology, ASST Bergamo Ovest, Treviglio, Bergamo, Italy.

Arianna Trizzino (A)

Unit of Surgical Oncology, ASST Bergamo Ovest, Treviglio, Bergamo, Italy.

Alfio A Russo (AA)

Unit of Surgical Oncology, ASST Bergamo Ovest, Treviglio, Bergamo, Italy.

Giovanni Sgroi (G)

Unit of Surgical Oncology, ASST Bergamo Ovest, Treviglio, Bergamo, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH